Cite

HARVARD Citation

    Sakai, H. et al. (n.d.). 493OTepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data. Annals of oncology. p. . [Online]. 
  
Back to record